Krystal Biotech (KRYS) Prepaid Assets (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Prepaid Assets of $15.3 million for Q2 2026, down 9.32% year-over-year from $16.9 million in Q2 2025, and down 4.48% on a QoQ basis from $16.0 million in Q1 2026.
Krystal Biotech (KRYS) Prepaid Assets (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Prepaid Assets for 11 years, with the latest figure at $15.3 million in Q2 2026.
- Prepaid Assets for Q2 2026 came in at $15.3 million, down 9.32% year-over-year; the trailing twelve-month figure through Jun 2026 was $15.3 million (down 9.32% YoY), and the FY2025 annual result was $14.9 million, up 27.86% from the prior year.
- Prepaid Assets eased to $15.3 million in Q2 2026, from $16.0 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $17.2 million in Q3 2025 and troughed at $3.2 million in Q3 2022.
- A 5-year average of $9.4 million and a median of $7.2 million in 2023 frame the typical range for Prepaid Assets.
- The widest annual swing landed in 2025, when Prepaid Assets jumped 158.29%; it then slipped 9.32% in 2026.
- A 5-year view of Prepaid Assets shows it stood at $4.6 million in 2022, then surged by 45.53% to $6.7 million in 2023, then surged by 73.83% to $11.7 million in 2024, then gained by 27.86% to $14.9 million in 2025, then advanced by 2.7% to $15.3 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $15.3 million in Q2 2026, $16.0 million in Q1 2026, and $14.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.31 Mn |
| Mar 31, 2026 | 10.64 Mn |
| Dec 31, 2025 | 14.01 Mn |
| Sep 30, 2025 | 17.21 Mn |
| Jun 30, 2025 | 16.88 Mn |
| Mar 31, 2025 | 16.75 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 8.96 Mn |
| Jun 30, 2024 | 7.75 Mn |
| Mar 31, 2024 | 6.49 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 5.47 Mn |
| Jun 30, 2023 | 6.49 Mn |
| Mar 31, 2023 | 5.04 Mn |
| Dec 31, 2022 | 4.61 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 3.21 Mn |
| Mar 31, 2022 | 3.37 Mn |
| Dec 31, 2021 | 4.17 Mn |
| Sep 30, 2021 | 2.72 Mn |